

REC'D 18 JUL 2005

WIPO

PCT

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITYTo:
DAVID A. RUBIN
126 EAST LINCOLN AVENUE
MERCK & CO., INC.
RAHWAY, NJ 07065-0907

PCT

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing
(day/month/year)

14 JUL 2005

Applicant's or agent's file reference

FOR FURTHER ACTION

See paragraph 2 below

PCT 21540

International application No.

International filing date (day/month/year)

Priority date (day/month/year)

PCT/US05/02454

26 January 2005 (26.01.2005)

28 January 2004 (28.01.2004)

International Patent Classification (IPC) or both national classification and IPC

IPC(7): A01N 43/64, 43/66, 43/58, 43/60; A61K 31/53, 31/495, 31/50; C07D 253/08, 487/00, 471/00, 241/36 and US Cl.:
514/243, 246, 249; 544/183, 184, 215, 279, 349

Applicant

MERCK & CO., INC.

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/ US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Zachary C. Tucker

Telephone No. (571) 272-1600

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US05/02454

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This opinion has been established on the basis of a translation from the original language into the following language _____, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

☐ a sequence listing

☐ table(s) related to the sequence listing

b. format of material

☐ in written format

☐ in computer readable form

c. time of filing/furnishing

☐ contained in international application as filed.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority for the purposes of search.

3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US05/02454

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims <u>1-27</u>	YES
	Claims <u>NONE</u>	NO
Inventive step (IS)	Claims <u>1-27</u>	YES
	Claims <u>NONE</u>	NO
Industrial applicability (IA)	Claims <u>1-27</u>	YES
	Claims <u>NONE</u>	NO

2. Citations and explanations:

Claims 1-27 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest compounds according to formulae I and II as set forth in instant claims 1-23, and therefore also does not teach or suggest a pharmaceutical composition comprising or a method of using the same, as set forth in instant claims 24-27.

Claims 1-27 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in the pharmaceutical and medical industries.

Relevant prior art comes from WO 03/092586 (JIAO et al), published 13 November 2003. The publication has inventors in common with the instant application. Compounds disclosed by JIAO et al are chemokine receptor modulators, and differ from the instantly claimed compounds in that no shared ring nitrogen is in the bicyclic ring moiety. JIAO et al's compounds share the 1-amino-3-carbonyl-cyclopentyl pharmacophore possessed by the compounds according to the instant application.